UNIGE document Scientific Article
previous document  unige:42493  next document
add to browser collection
Title

Dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial

Authors
Montagne, Agnes
show hidden authors show all authors [1 - 10]
Published in Pain Physician. 2013, vol. 16, no. 5, p. E553-62
Abstract Investigations based on quantitative sensory testing have consistently shown evidence of allodynia in fibromyalgia syndrome (FMS) patients involving both the spinal and supraspinal pain regulatory systems. Functional imaging studies have demonstrated enhanced neural activities in pain-related brain areas as well as impairment of pain inhibition in the descending nociceptive regulatory system. A higher state of excitability of spinal nociceptive neurons as evidenced by lowered nociceptive flexion reflex R-III (NFR) threshold was reported for FMS patients. The NFR procedure has been shown to be a valuable tool to evaluate pharmacologically active therapeutic agents at the spinal level.
Keywords AdultAgedAntidepressive Agents/administration & dosage/therapeutic useCyclopropanes/administration & dosage/therapeutic useDouble-Blind MethodFemaleFibromyalgia/drug therapyHumansMaleMiddle AgedPain/drug therapyPain Measurement/methodsSpinal Diseases/drug therapyTreatment Outcome
Identifiers
PMID: 24077206
Full text
Article (Published version) (337 Kb) - public document Free access
Structures
Research groups Epidémiologie clinique (115)
Groupe Pierre Dayer (pharmacologie/toxicologie) (78)
Groupe Desmeules Jules (pharmacologie/toxicologie) (567)
Citation
(ISO format)
MATTHEY, Alain et al. Dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial. In: Pain Physician, 2013, vol. 16, n° 5, p. E553-62. https://archive-ouverte.unige.ch/unige:42493

176 hits

863 downloads

Update

Deposited on : 2014-12-04

Export document
Format :
Citation style :